significantly in Medical Technology

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that Vectibix((R)) (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with F...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that R788 (fostamatinib disodium) produced significant clinical improvement in rheumatoid arthritis (RA) patients in the recently completed TASKi2 Phase 2b clinical trial of ...

Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia

PALO ALTO, Calif., June 15 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals' (Nasdaq: JAZZ ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last we...

Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment

Journal of Vascular & Interventional Radiology Cites Improved Recovery and Quality-of-Life with VNUS Technology SAN JOSE, Calif., June 10 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide leader in medical devices for the minimally invasive tr...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (Toci LI zumab Safety and THE Prevention of Structural Joint Damage) study de...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

Studies Advocate Blood Conservation and Appropriate Indicators for Transfusion IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that two new studies - ...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ -- - Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and its fully owned subsidiary, BiPar Sciences, today announced resu...

Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain

--Data from Phase 3 REDUCE-1 and REDUCE-2 Studies Demonstrate that Novel Combination Treatment Decreases Risk of Developing GI Ulcers by Approximately 50 Percent-- --Data presented today at 56th Annual Digestive Disease Week Meeting in Chicago-- CHICAGO, June 1 /PRNewswire/ -- Horizon T...

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

AZTEC Trial First to Examine AZOR Using 24-Hour Ambulatory BP Measures PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San ...

Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

-Clinical Data Presented at American Pain Society Annual Meeting- BALTIMORE, May 7 /PRNewswire/ -- Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, today announced the presentation of data demonstrating that its lead candidate, ARC...

Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer

Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be pr...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreo...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

48-week investigational regimen yielded nearly double SVR rate compared to standard of care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) toda...

Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density

INDIANAPOLIS, April 8 /PRNewswire-FirstCall/ -- Phase III data, published online this week in the Journal of Clinical Endocrinology & Metabolism , showed that arzoxifene, an investigational selective estrogen receptor modulator (SERM) being developed by Eli Lilly and Company (NYSE: LLY ), s...

Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap

QIAGEN donates one million tests to expand access to HPV screening in the world's poorest countries VENLO, Netherlands, April 1 /PRNewswire-FirstCall/ -- Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonst...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

GENEVA, Feb. 3 /PRNewswire/ -- -- The Six-Month Primary Efficacy Endpoint of the Study was met: Both Doses of Investigational Agent Safinamide Significantly Increased "ON" Time in Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease -- Secondary Efficacy Endpoi...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

INDIANAPOLIS, Jan. 30 /PRNewswire-FirstCall/ -- In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week randomized, double-blind, placebo-controlle...

Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy

SEATTLE, Dec. 6 /PRNewswire-FirstCall/ -- Results from RESTORE 2, a placebo-controlled, Phase III study demonstrated that the investigational compound retigabine significantly reduced the number of seizures in adult patients with refractory partial-onset epilepsy when a 600 mg or 900 mg dose was a...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

- Results Presented at ASH Annual Meeting- SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK ) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocyto...

Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death

Long-term benefits of preventing heart attacks highlighted in new study presented at global health outcomes meeting ATHENS, Greece, Nov. 9 /PRNewswire-FirstCall/ -- Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart ...

Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder

First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov. 1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a ne...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

- Results of two Phase III studies affirmed the clinical benefits of ACTEMRA - NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in sig...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in th...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

NYON, Switzerland, September 16 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company's mucosal HIV-AIDS vaccine designed for trigg...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

MUNICH, Germany, Sept. 3 /PRNewswire-FirstCall/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless of whether ...

'Hibernation-On-Demand' Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss

Findings in rats show promise for 'buying time' in victims of lethal hemorrhage SEATTLE, July 1 /PRNewswire/ -- For the first time, researchers have demonstrated that the administration of minute amounts of inhaled or intravenous hydrogen sulfide, or H2S -- the ...

Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia

Study Meets Primary Endpoint, with Positive Effect Sustained Through Duration of 4-Week Study ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) (Vanda) today announced positive top-line results from a Phase III trial showing ...

New Study: Pine Bark Significantly Reduces Menstrual Pain

Multi-center Field Study Reveals Pycnogenol(R) Reduces Need for Dysmenorrhea Pain Medication HOBOKEN, N.J., June 18 /PRNewswire/ -- A new study reveals dysmenorrhea, a condition that causes extremely painful menstrual periods affecting millions of women each year, can ...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

New Data Highlights the Need for Testosterone Screening in At-Risk Hypogonadal Men BEDMINSTER, N.J., June 17 /PRNewswire/ -- New data from a 12-month, international, multi-center study showed that treatment for low testosterone with Tostran(R), a topical, metered ...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

- Phase III monotherapy study shows ACTEMRA is first and only biologic to demonstrate statistical superiority over methotrexate after 24 weeks of treatment - PARIS, June 13 /PRNewswire/ -- Patients who suffer the chronic and debilitating effects of rheumatoid arth...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced Improvements in Physical Function and Disease Activity PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNT...

Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer

- Data From Pivotal Phase III AVADO Study Presented at ASCO for the First Time BASEL, Switzerland, May 31 /PRNewswire/ -- Avastin (bevacizumab), significantly improves the time patients with metastatic breast cancer live without their disease getting worse ("pro...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

New Data to be Presented at ASCO Shows Survival Benefit in Complete and Partial Responders Compared with Chemotherapy Alone BERKELEY HEIGHTS, N.J., May 29 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced the results of long-term followup from a Phase 3...

Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer

Analysis Reveals Overall Survival Could be Extended if Patients Receive the Most Effective Treatment Identified by ChemoFx CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific...

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

- Trial Results Confirm Efficacy for Population Most Affected by Disease - WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that Nexavar(R) (sorafenib) tablets significantl...

Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents

Phase III Data Presented at American Psychiatric Association Annual Meeting WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) announced today that study results show Lexapro (escitalopram oxalate) significantly improved symptoms of depression as compared to plac...

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

Separate Study Showed Significantly Improved Functioning Within Three Months WASHINGTON, May 6 /PRNewswire-FirstCall/ -- Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of symptoms (1,2). To...

Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year

- Cognitive Function Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients treated with the investigatio...

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

Additional Data Demonstrate Predictable, Extended Exposure with Sustained- Release Formulation CHICAGO, April 17 /PRNewswire/ -- Data from the first pivotal study of XP13512/GSK1838262, a sustained-release investigational compound to treat Restless Legs Syndrome (RLS), ...